Schonfeld Strategic Advisors LLC Trims Position in United Therapeutics Co. (NASDAQ:UTHR)

Schonfeld Strategic Advisors LLC lowered its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 28.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,400 shares of the biotechnology company's stock after selling 1,733 shares during the period. Schonfeld Strategic Advisors LLC's holdings in United Therapeutics were worth $1,552,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of UTHR. Signaturefd LLC lifted its holdings in United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock worth $234,000 after purchasing an additional 30 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of United Therapeutics by 2.8% in the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after acquiring an additional 30 shares during the period. Anchor Investment Management LLC grew its stake in United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 30 shares in the last quarter. Great Lakes Advisors LLC grew its stake in United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after acquiring an additional 31 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its stake in United Therapeutics by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock worth $3,214,000 after purchasing an additional 33 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the transaction, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, April 17th. The stock was sold at an average price of $283.78, for a total value of $3,121,580.00. Following the transaction, the executive vice president now owns 36,781 shares in the company, valued at $10,437,712.18. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 65,500 shares of company stock worth $20,765,280 in the last ninety days. Insiders own 11.90% of the company's stock.

United Therapeutics Stock Performance

NASDAQ UTHR traded up $3.83 on Monday, reaching $305.25. 89,830 shares of the stock traded hands, compared to its average volume of 439,127. The company has a market cap of $13.77 billion, a price-to-earnings ratio of 13.41, a PEG ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a 12 month low of $263.56 and a 12 month high of $417.82. The company has a fifty day moving average price of $300.53 and a 200-day moving average price of $342.01.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same period last year, the company earned $6.17 earnings per share. United Therapeutics's revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on UTHR. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. HC Wainwright reiterated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. JPMorgan Chase & Co. dropped their target price on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. Finally, Morgan Stanley increased their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a report on Thursday, May 1st. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $392.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.